One of Antisense Therapeutics' fundamental strategies is acquiring access to state of the art antisense technology, in both know-how and intellectual property, to accelerate drug discovery and development.
Ionis and the ATL/Ionis Partnership
As a leader in the field, the directors believe that Ionis Pharmaceuticals, Inc. is the ideal technology partner for Antisense Therapeutics.
Ionis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Ionis’ mission is to develop products from its RNA-based technologies, such as antisense.
California-based Isis is the leader in all aspects of antisense technology advancement, including mechanism research, the development of new chemistries, novel formulations and innovative drugs. The company currently has 28 products in development to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases and cancer.
Ionis is the owner of one of the largest antisense and RNA patent estates in the pharmaceutical industry. The Company holds key patents covering antisense mechanisms, biology, chemistry, inhibitors of gene expression and manufacturing of antisense drugs.
Ionis has alliances with a number of global pharmaceutical companies, including Genzyme, GSK, Biogen Idec and Pfizer. Isis’ partner Genzyme is commercialising Ionis’ lead product KYNAMRO™ in the United States for the treatment of patients with Homozygous Familial Hypercholesterolemia and is the first antisense drug approved for systemic (injectable) administration. Genzyme is also pursuing marketing approval of KYNAMRO in other markets.